These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9178754)

  • 1. FLP recombinase/estrogen receptor fusion proteins require the receptor D domain for responsiveness to antagonists, but not agonists.
    Nichols M; Rientjes JM; Logie C; Stewart AF
    Mol Endocrinol; 1997 Jun; 11(7):950-61. PubMed ID: 9178754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive and negative discrimination of estrogen receptor agonists and antagonists using site-specific DNA recombinase fusion proteins.
    Logie C; Nichols M; Myles K; Funder JW; Stewart AF
    Mol Endocrinol; 1998 Aug; 12(8):1120-32. PubMed ID: 9717838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different positioning of the ligand-binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists.
    Nichols M; Rientjes JM; Stewart AF
    EMBO J; 1998 Feb; 17(3):765-73. PubMed ID: 9451001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor.
    Gee AC; Carlson KE; Martini PG; Katzenellenbogen BS; Katzenellenbogen JA
    Mol Endocrinol; 1999 Nov; 13(11):1912-23. PubMed ID: 10551784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular modelling of the human estrogen receptor and ligand interactions based on site-directed mutagenesis and amino acid sequence homology.
    Lewis DF; Parker MG; King RJ
    J Steroid Biochem Mol Biol; 1995 Jan; 52(1):55-65. PubMed ID: 7857874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor.
    Kim S; Brown PH; Birrer MJ
    Oncogene; 1996 Mar; 12(5):1043-53. PubMed ID: 8649795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization by mass spectrometry of the human estrogen receptor ligand-binding domain expressed in Escherichia coli.
    Seielstad DA; Carlson KE; Katzenellenbogen JA; Kushner PJ; Greene GL
    Mol Endocrinol; 1995 Jun; 9(6):647-58. PubMed ID: 8592511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma.
    Coward P; Lee D; Hull MV; Lehmann JM
    Proc Natl Acad Sci U S A; 2001 Jul; 98(15):8880-4. PubMed ID: 11447273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yeast two-hybrid system demonstrates that estrogen receptor dimerization is ligand-dependent in vivo.
    Wang H; Peters GA; Zeng X; Tang M; Ip W; Khan SA
    J Biol Chem; 1995 Oct; 270(40):23322-9. PubMed ID: 7559488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains.
    Feil R; Wagner J; Metzger D; Chambon P
    Biochem Biophys Res Commun; 1997 Aug; 237(3):752-7. PubMed ID: 9299439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase.
    Metzger D; Clifford J; Chiba H; Chambon P
    Proc Natl Acad Sci U S A; 1995 Jul; 92(15):6991-5. PubMed ID: 7624356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand-activated Flpe for temporally regulated gene modifications.
    Hunter NL; Awatramani RB; Farley FW; Dymecki SM
    Genesis; 2005 Mar; 41(3):99-109. PubMed ID: 15729687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporally distinct and ligand-specific recruitment of nuclear receptor-interacting peptides and cofactors to subnuclear domains containing the estrogen receptor.
    Schaufele F; Chang CY; Liu W; Baxter JD; Nordeen SK; Wan Y; Day RN; McDonnell DP
    Mol Endocrinol; 2000 Dec; 14(12):2024-39. PubMed ID: 11117532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of Cre recombinase toxicity in proliferating Drosophila cells by estrogen-dependent activity regulation.
    Heidmann D; Lehner CF
    Dev Genes Evol; 2001 Sep; 211(8-9):458-65. PubMed ID: 11685583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The unusual binding properties of the third distinct teleost estrogen receptor subtype ERbetaa are accompanied by highly conserved amino acid changes in the ligand binding domain.
    Hawkins MB; Thomas P
    Endocrinology; 2004 Jun; 145(6):2968-77. PubMed ID: 15001543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular determinants of tissue selectivity in estrogen receptor modulators.
    Grese TA; Sluka JP; Bryant HU; Cullinan GJ; Glasebrook AL; Jones CD; Matsumoto K; Palkowitz AD; Sato M; Termine JD; Winter MA; Yang NN; Dodge JA
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):14105-10. PubMed ID: 9391160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand-regulated site-specific recombination.
    Logie C; Stewart AF
    Proc Natl Acad Sci U S A; 1995 Jun; 92(13):5940-4. PubMed ID: 7597057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-estrogen hydroxytamoxifen is a potent antagonist in a novel yeast system.
    Liu JW; Jeannin E; Picard D
    Biol Chem; 1999 Nov; 380(11):1341-5. PubMed ID: 10614829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probing the structure and function of the estrogen receptor ligand binding domain by analysis of mutants with altered transactivation characteristics.
    Eng FC; Lee HS; Ferrara J; Willson TM; White JH
    Mol Cell Biol; 1997 Aug; 17(8):4644-53. PubMed ID: 9234721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bivalent ligands as probes of estrogen receptor action.
    Bergmann KE; Wooge CH; Carlson KE; Katzenellenbogen BS; Katzenellenbogen JA
    J Steroid Biochem Mol Biol; 1994 Jun; 49(2-3):139-52. PubMed ID: 8031710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.